CATALYST PHARMACEUTICALS, INC.

Catalyst Pharmaceuticals is a commercial-stage biopharmaceutical company headquartered in Coral Gables, Florida, that develops and commercializes medications for rare diseases. The company's primary marketed products include Firdapse and Ruzurgi for lambert-eaton myasthenic syndrome (LEMS), Fycompa for focal onset and tonic-clonic seizures, and AGAMREE, a corticosteroid for duchenne muscular dystrophy. These products target patient populations with limited treatment options and represent the company's core revenue streams in the U.S. market.

The company maintains licensing agreements with external partners to support its product portfolio and pipeline. Catalyst holds a collaboration and license agreement with Endo Ventures Limited for generic Sabril tablet development and commercialization, and has partnerships with BioMarin Pharmaceutical Inc. for additional assets. The company operates with approximately 181 full-time employees and maintains its commercial operations in the United States. Founded in 2002, Catalyst operates as a publicly traded company listed on the Nasdaq and is incorporated in Delaware.